



SEQUENCE LISTING

<110> SAIKAWA, Akira
IGARI, Yasutaka
HATA, Yoshio
YAMAMOTO, Kazumichi

<120> Sustained-Release Composition, Method of its Preparation and Use Thereof

<130> 2500US1P

<140> 10/799,320
<141> 2004-03-12

<150> 09/582,926
<151> 2000-07-05

<150> PCT/JP99/00086
<151> 1999-01-13

<150> JP 10-6412
<151> 1998-01-16

<160> 5

<170> PatentIn version 3.0

<210> 1
<211> 11
<212> PRT
<213> artificial

<220>
<223> LH-RH derived peptide

<220>
<221> MOD_RES
<222> (1)..(1)
<223> X is 5-oxo carboxy terminal

<220>
<221> MOD_RES
<222> (7)..(7)
<223> X is "Y" which can be DLeu, DAla, DTrp, DSer(tbut), D2Nal or DHis
(ImBzl

<220>
<221> MOD_RES
<222> (11)..(11)
<223> X is "Z" which can be NH-C2H5 or Gly-NH2

<400> 1

Xaa Pro His Trp Ser Tyr Xaa Leu Arg Pro Xaa
 1 5 10

<210> 2
 <211> 11
 <212> PRT
 <213> artificial

<220>
 <223> LH-RH antagonist derivatives

<220>
 <221> MOD_RES
 <222> (1)..(1)
 <223> X is "X" which can be N(4H2-furoyl)Gly or NAc

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> X is D2Nal

<220>
 <221> MOD_RES
 <222> (3)..(3)
 <223> X is D4ClPhe

<220>
 <221> MOD_RES
 <222> (4)..(4)
 <223> X is D3Pal

<220>
 <221> MOD_RES
 <222> (6)..(6)
 <223> X is "A" which can be NMeTyr, Tyr, Aph(Atz) or NMeAph(Atz)

<220>
 <221> MOD_RES
 <222> (7)..(7)
 <223> X is "B" which can be DLys(Nic), DCit, DLys(AzaGlyNic), DLys(AzaGlyFur), DhArg(Et2), DAph(Atz), or DhC

<220>
 <221> MOD_RES
 <222> (9)..(9)
 <223> X is "C" which can be Lys(Nisp), Arg or HArg(Et2)

<220>
 <221> MOD_RES
 <222> (11)..(11)

<223> X is DAlaNH2

<400> 2

Xaa Xaa Xaa Xaa Ser Xaa Xaa Leu Xaa Pro Xaa
1 5 10

<210> 3

<211> 10

<212> PRT

<213> artificial

<220>

<223> LH-RH derived peptides

<220>

<221> MOD_RES

<222> (1)..(1)

<223> X is 5-oxo carboxy terminal

<220>

<221> MOD_RES

<222> (7)..(7)

<223> X is DLeu

<220>

<221> MOD_RES

<222> (10)..(10)

<223> X is NH-C2H5 amino terminal

<400> 3

Xaa Pro His Trp Ser Tyr Xaa Arg Pro Xaa
1 5 10

<210> 4

<211> 12

<212> PRT

<213> artificial

<220>

<223> LH-RH derived peptides

<220>

<221> MOD_RES

<222> (1)..(1)

<223> X is N-(S)-tetrahydrofur-2-oyl-

<220>

<221> MOD_RES

<222> (3)..(3)

<223> X is D2Nal

<220>
 <221> MOD_RES
 <222> (4)..(4)
 <223> X is D4ClPhe

<220>
 <221> MOD_RES
 <222> (5)..(5)
 <223> X is D3Pal

<220>
 <221> MOD_RES
 <222> (7)..(7)
 <223> X is NMeTyr

<220>
 <221> MOD_RES
 <222> (8)..(8)
 <223> X is DLys(Nic)

<220>
 <221> MOD_RES
 <222> (10)..(10)
 <223> X is Lys(Nisp)

<220>
 <221> MOD_RES
 <222> (12)..(12)
 <223> X is DAlaNH2

<400> 4

Xaa Gly Xaa Xaa Xaa Ser Xaa Xaa Leu Xaa Pro Xaa
 1 5 10

<210> 5
 <211> 11
 <212> PRT
 <213> artificial

<220>
 <223> LH-RH derived peptides

<220>
 <221> MOD_RES
 <222> (1)..(1)
 <223> X is 5-oxo carboxy terminal

<220>
<221> MOD_RES
<222> (7)..(7)
<223> X is DLeu

<220>
<221> MOD_RES
<222> (11)..(11)
<223> X is NH-C2H5 amino terminal

<400> 5

Xaa	Pro	His	Trp	Ser	Tyr	Xaa	Leu	Arg	Pro	Xaa
1				5					10	